Last reviewed · How we verify
RA-18C3
At a glance
| Generic name | RA-18C3 |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis (PHASE2)
- Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RA-18C3 CI brief — competitive landscape report
- RA-18C3 updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI